Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease

Protein Science

Volumn 8, Issue 1, 1999, Pages 180-195

  Trylska, Joanna ^a   Antosiewicz, Jan ^a   Geller, Maciej ^a   Hodge, Nicholas ^b   Klabe, Ronald M ^b   Head, Martha S ^c   Gilson, Michael K ^c  

^a UNIVERSITY OF WARSAW   (Poland)

^b DUPONT COMPANY   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

Binding; Cyclic urea; HIV 1 protease; Inhibitor; PK(a)

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ASPARTIC ACID; KYNOSTATIN 272; MVT 101; PROTEINASE INHIBITOR; PROTON; UNCLASSIFIED DRUG; UREA; XK 263;

ARTICLE; BINDING AFFINITY; CALCULATION; DIELECTRIC CONSTANT; ENZYME BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PH; PKA; PRIORITY JOURNAL; PROTON TRANSPORT; THERMODYNAMICS;

EID: 0032898499     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.8.1.180     Document Type: Article

References (92)

1. Alexov EG, Gunner MR. 1997. Incorporating protein conformational flexibility into the calculation of pH-dependent protein properties. Biophys J 72:2075-2093.
2. Antosiewicz J, Briggs JM, Elcock AH, Gilson MK, McCammon JA. 1996a. Computing the ionization states of proteins with a detailed charge model. J Comput Chem 17:1633-1644.
3. Antosiewicz J, McCammon JA, Gilson MK. 1994. Prediction of pH-dependent properties of proteins. J Mol Biol 238:415-436.
4. as in proteins. Biochemistry 35:7819-7833.
5. Baldwin ET, Bhat TN, Gulnik S, Liu B, Topol IA, Kiso Y, Mimoto T, Mitsuya H, Erickson JW. 1995. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 3:581-590.
6. a values in myoglobin and comparison with NMR data for histidines. Biochemistry 32:8045-8056.
7. a values of ionizable groups in bacteriorhodopsin. J Mol Biol 224(2):473-486.
8. a's of ionizable groups in proteins: Atomic detail from a continuum electrostatic model. Biochemistry 29:10219-10225.
9. Bashford D, Karplus M. 1991. Multiple-site titration curves of proteins: An analysis of exact and approximate methods for their calculation. J Phys Chem 95:9556-9561.
10. Bernstein FC, Koetzle TF, Williams TF, Meyer GJB Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. 1977. The Protein Data Bank: A computer-based archival file for macromolecular structures. J Mol Biol 112:535-542.
11. Beroza P, Fredkin DR, Okamura MY, Feher G. 1991. Protonation of interacting residues in a protein by a Monte Carlo method: Application to lysozyme and the photosynthetic reaction center of Rhodobacter sphaeroides. Proc Natl Acad Sci USA 88:5804-5808.
12. Beveridge AJ, Heywood GC. 1993. A quantum mechanical study of the active site of aspartic proteinases. Biochemistry 32:3325-3333.
13. Brocklehurst K. 1994. A sound basis for pH-dependent kinetic studies on enzymes. Protein Eng 7:291-299.
14. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. 1983. CHARMm: A program for macromolecular energy, minimization and dynamics calculations. J Comput Chem 4:187-217.
15. Brunger AT, Karplus M. 1988. Polar hydrogen positions in proteins: Empirical energy placement and neutron diffraction comparison. Proteins Struct Funct Genet 4:148-156.
16. CHARMm Version 22. 1992. Polar hydrogen parameter set for CHARMm Version 22. Waltham, Massachusetts: Molecular Simulations Inc.
17. Chatfield DC, Brooks BR. 1995. HIV-1 protease cleavage mechanism elucidated with molecular dynamics simulation. J Am Chem Soc 117:5561-5572.
18. Cheng YS, Yin FH, Foundling S, Blomstrom D, Kettner CA. 1990. Stability and activity of Human Immunodeficiency Virus protease: Comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc Natl Acad Sci USA 87:9660-9664.
19. Cleland WW. 1977. Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies. Adv Enzymol Relat Areas Mol Biol 45:273-387.
20. Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, Rosenberg M. 1987. Human Immunodeficiency Virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci USA 84:8903-8906.
21. as of ionizable groups in proteins. J Phys Chem 100:17373-17387.
22. Erickson-Viitanen S, Klabe RM, Cawood PG, O'Neal PL, Meek JL. 1994. Potency and selectivity of inhibition of Human Immunodeficiency Virus protease by a small nonpeptide cyclic urea. DMP 323. Antimicrob Agents Chemother 38:1628-1634.
23. Fersht A. 1985. Enzyme structure and mechanism, 2nd ed. New York: W.H. Freeman and Co.
24. Geller M, Miller M, Swanson SM, Maizel J. 1997. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamics studies of the active site region. Proteins Struct Funct Genet 27:195-203.
25. a calculations. Biophys J 71:138-147.
26. Gilson MK. 1993. Multiple-site titration and molecular modelling: Two rapid methods for computing energies and forces for ionizable groups in proteins. Proteins Struct Funct Genet 15:266-282.
27. Gilson MK. 1997. Modeling protonation equilibria in biomolecules. In: Gunsteren WFV, Weiner PK, Wilkinson AJ, eds. Computer simulations of biomolecular systems, Vol. 3. Dordrecht: Kluwer/Escom. pp 199-222.
28. Gilson MK, Honig B. 1988a. Calculation of the total electrostatic energy of a macromolecular system: Solvation energies, binding energies and conformational analysis. Proteins Struct Funct Genet 4:7-18.
29. Gilson MK, Honig B. 1988b. Energetics of charge-charge interactions in proteins. Proteins Struct Funct Genet 3:32-52.
30. Gilson MK, Honig BH. 1986 The dielectric constant of a folded protein. Biopolymers 25:2097-2119.
31. Gilson MK, Rashin AA, Fine R, Honig B. 1985. On the calculation of electrostatic interactions in proteins. J Mol Biol 183:503-516.
32. Goldblum A, Glick M, Rayan A. 1993. Determining proton positions in an enzyme-inhibitor complex is a first step for theoretical mechanistic studies of aspartic proteinases. Theor Chim Acta 85:231-247.
33. Grant SK, Deckman IC, Culp JS, Minnich MD, Brooks IS, Hensley P, Debouck C, Meek TD. 1992. Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV-1 proteases. Biochemistry 31:9491-9501.
34. Graves MC, Lim JJ, Heimer EP, Kramer RA. 1988. An 11-kDa form of Human Immunodeficiency Virus protease expressed in Escherichia coli is sufficient for enzymatic activity. Proc Natl Acad Sci USA 85:2449-2453.
35. 3O+. J Mol Struct (Theochem) 150:241-250.
36. Hansen J, Billich S, Shulze T, Sukrow S, Moelling K. 1988. Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. Embo J 7:1785-1791.
37. Harte WE Jr, Beveridge DL. 1993. Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation. J Am Chem Soc 115:3883-3886.
38. Hawkins GD, Cramer CJ, Truhlar DG. 1995. Pairwise solute descreening of solute charges from a dielectric medium. Chem Phys Lett 246:122-129.
39. Hyland LJ, Tomaszek TA Jr, Meek TD. 1991. Human Immunodeficiency Virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30:8454-8463.
40. Ido E, Han HP, Kezdy FJ, Tang J. 1991. Kinetic studies of Human Immunodeficiency Virus type 1 protease and its active-site hydrogen bond mutant A28S. J Biol Chem 266:24349-24366.
41. Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, Bacheler LT. 1997. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem 40:181-191.
42. Jaskolski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrikson RL, Schneider J, Kent SBH, Wlodawer A. 1991. Structure at 2.5 Angstrom resolution of chemically synthesized Human Immunodeficiency Virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 30:1600-1609.
43. Jorgensen WL, Tirado-Rives J. 1988. The OPLS potential function for proteins. Energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657-1666.
44. Kageyama S, Mimoto T, Murakawa Y, Nomizu M, Ford H, Shirasaka T, Gulnik S, Erickson J, Takada K, Hayashi H, et al. 1993. In vitro anti-human-immunodeficiency-virus (HIV) activities of transition-state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother 37:810-817.
45. Kick EK, Roe DC, Skillman AG, Liu G, Ewing TJA, Sun Y, Kuntz ID, Ellman JA. 1997. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem Biol 4:297-307.
46. King G, Lee FS, Warshel A. 1991. Microscopic simulations of macroscopic dielectric constants of solvated proteins. J Chem Phys 95:4366-4377.
47. Klapper I, Hagstrom R, Fine R, Sharp K, Honig B. 1986. Focusing of electric fields in the active site of Cu,Zn superoxide dismutase. Proteins Struct Funct Genet 1:47-79.
48. a-values of functional groups in enzymes: Improper deductions from the pH-dependence of steady-state parameters. CRC Crit Rev Biochem 4:165-173.
49. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. 1988. Active Human Immunodeficiency Virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85:4686-4690.
50. Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang CH, Emmett G, Holler ER, Daneker WF, et al. 1996. Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem 39:3514-3525.
51. Lam PYS, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN, et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380-384.
52. Lee H, Darden TA, Pedersen LG. 1996. An ab initio quantum mechanical model for the catalytic mechanism of HIV-1 protease. J Am Chem Soc 118:3946-3950.
53. Liu H, Muller-Plathe F, van Gunsteren WF. 1996. A combined quantum/ classical molecular dynamics study of the catalytic mechanism of HIV protease. J Mol Biol 261:454-469.
54. a shifts in small molecules and HIV protease: Electrostatics and conformation. J Am Chem Soc 120:6138-6146.
55. Matthew JB, Gurd FRN, Garcia-Moreno BE, Flanagan MA, March KL, Shire SJ. 1985. pH-Dependent processes in proteins. Crit Rev Biochem 18:91-197.
56. 13C-NMR study of Bacillus circulans xylanase. Biochemistry 35:9958-9966.
57. Mildner AM, Rothrock DJ, Leone JW, Bannow CA, Lull JM, Reardon IM, Sarcich JL, Howe WJ, Tomich CSC, et al. 1994. The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 33:9405-9413.
58. Miller M, Geller M, Gribskov M, Kent SBH. 1997. Analysis of the structure of chemically synthesized HIV-1 protease complexed with a hexapeptide inhibitor. Part I: Cristallographic refinement of 2 Angstrom data. Proteins Struct Funct Genes 27:184-194.
59. Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, Wlodawer A. 1989. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Angstrom resolution. Science 246:1149-1152.
60. Moore ML, Bryan WM, Fakhoury SA, Magaard VW, Huffman WF, Dayton BD, Meek TD, Hyland L, Dreyer GB, Metcalf BW, et al. 1989. Peptide-substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun 159:420-425.
61. Muir TW, Williams MJ, Kent SBH. 1995. Detection of synthetic protein isomers and conformers by electrospray mass spectrometry. Anal Biochem 224:100-109.
62. Nozaki Y, Tanford C. 1967. Examination of titration behavior. Methods Enzymol 11:715-734.
63. Oberoi H, Allewell NM. 1993. Multigrid solution of the nonlinear Poisson-Boltzmann equation and calculation of titration curves. Biophys J 65:48-55.
64. Oda Y, Yamazaki T, Nagayama K, Kanaya S, Kuroda Y, Nakamura H. 1994. Individual ionization constants of all the carboxyl groups in ribonuclease H from Escherichia coli determined by NMR. Biochemistry 33:5275-5284.
65. Qiu D, Shenkin PS, Hollinger FP, Still WC. 1997. The GB/SA continuum model for salvation. A fast analytical method for the calculation of approximate born radii. J Phys Chem 101:3005-3014.
66. Rich DH, Green J, Toth MV, Marshall GR, Kent SBH. 1990. Hydroxyethylamine analogs of the P17/P24 substrate cleavage site are tight-binding inhibitors of HIV protease. J Med Chem 33:1285-1288.
67. Schellman JA. 1975. Macromolecular binding. Biopolymers 14:999-1018.
68. Schock HB, Garsky VM, Kuo LC. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials - Compensatory modulations of binding and activity. J Biol Chem 271:31957-31963.
69. Shire SJ, Hanania GIH, Gurd FRN. 1974. Electrostatic effects in myoglobin. Hydrogen ion equilibria in sperm whale ferrimyoglobin. Biochemistry 13:2967-2974.
70. Silva AM, Cachau RE, Sham HL, Erickson JW. 1996. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J Mol Biol 255:321-346.
71. Simonson T, Perahia D. 1995. Internal and interfacial dielectric properties of cytochrome C from molecular dynamics in aqueous solution. Proc Natl Acad Sci USA 92:1082-1086.
72. Simonson T, Perahia D, Brunger AT. 1991. Microscopic theory of the dielectric properties of proteins. Biophys J 59:670-690.
73. Sitkoff D, Sharp KA, Honig B. 1994. Accurate calculation of hydration free energies using macroscopic solvation models. J Phys Chem 98:1978-1988.
74. Smith AB III, Hirschmann R, Pasternak A, Guzman MC, Yokoyama A, Sprengeler PA, Darke PL, Emini EA, Schleif WA. 1995. Pyrrolinone-based HIV protease inhibitors. Design, synthesis and antiviral activity: Evidence for improved transport. J Am Chem Soc 117:11113-11123.
75. Smith R, Breton IM, Chai RY, Kent SBH. 1997. Ionization states of the catalytic residues in HIV-1 protease. Nat Struct Biol 3:946-950.
76. Spinelli S, Liu QZ, Alzari PM, Hirel PH, Poljak RJ. 1991 The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 73:1391.
77. Still WC, Tempczyk A, Hawley RC, Hendrickson T. 1990. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 112:6127-6129.
78. a values of active site residues. Biochemistry 35:814-823.
79. Stryer L. 1981. Biochemistry, 2nd ed. New York: W.H. Freeman and Co.
80. Tipton KF, Dixon HBF. 1979. Effects of pH on enzymes. Methods Enzymol 63:183-234.
81. Todd M, Semo N, Freire E. 1998. The structural stability of the HIV-1 protease. J Mol Biol 283:475-488.
82. Tomasselli AG, Mildner AM, Rothrock DJ, Sarcich JL, Lull J, Leone J, Heinrikson RL. 1995. Mutants of HIV-1 protease with enhanced stability to auto-degradation. Adv Exp Med Biol 362:387-398.
83. Wang Y-X, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ, Kaufman JD, Kiso Y, Torchia DA. 1996. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 35:9945-9950.
84. Warwicker J, Watson HC. 1982. Calculation of the electric potential in the active site cleft due to alpha-helix dipoles. J Mol Biol 157:671-679.
85. Weast RC, ed. 1975. Handbook of chemistry and physics. Washington, DC: CRC Press.
86. Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SBH. 1989. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
87. Wyman J. 1965. The binding potential, a neglected linkage concept. J Mol Biol 11:631-644.
88. Xie D, Gulnik S, Collins L, Gustchina E, Suvorov L, Erickson JW. 1997. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: Direct measurement of the protonation states of the catalytic aspartic acid residues. Biochemistry 36:16166-16172.
89. Yamazaki T, Nicholson LK, Torchia DA, Wingfield P, Stahl SJ, Kaufman JD, Eyermann CJ, Hodge CN, Lam PYS, Ru Y, et al. 1994. NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor. J Am Chem Soc 116:10791-10792.
90. as in proteins. Proteins Struct Funct Genet 15:252-265.
91. Yang AS, Honig B. 1993. On the pH dependence of protein stability. J Mol Biol 231:459-474.
92. Zhang Z, Poorman RA, Maggiora LL, Heinrikson R, Kezdy F. 1991. Dissociative inhibition of dimeric enzymes - Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem 266:15591-15594.